Listen to a recording of the May 2019 Scientific Update Meeting Listen to M4K Pharma's Scientific Update Meeting from May 8th, 2019 where our scientists and collaborators discuss the latest progress in our Medicines4Kids project for a deadly children's brain cancer called DIPG. Everyone is invited to hear first-hand how we are [...]
Medicines for Neurodegeneration (M4ND) Pharma launched! Following in the path of M4K Pharma, M4ND will tackle neurodegenerative diseases such as Parkinson’s disease, thanks to funding from the Krembil Foundation, and will commit to open science practises, open sharing of data, and affordable pricing. https://www.utoronto.ca/news/u-t-researcher-s-open-science-drug-discovery-model-expands-neurodegenerative-diseases
Regulatory exclusivity as a primary intellectual property and commercial asset How can a company take advantage of regulatory exclusivity to launch an open science drug discovery program? Max Morgan et al explain in their paper Ideation and implementation of an open science drug discovery business model - M4K Pharma published in Welcome Open Research this month. Comparing [...]
